App-Quantinova.ai

Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with Trastuzumab

PS Blanchette - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Alkaline phosphatase

Nuclear grade has a limited role in predicting recurrence in DCIS following breast conserving surgery: A population-based study

S Nofech-Mozes - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

The role of quantitative estrogen receptor status in predicting breast tumor response to neoadjuvant chemotherapy

J Raphael - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Umirolimus

A randomized, double-blind, placebo-controlled window of opportunity trial evaluating clinical effects of high dose vitamin D in patients with breast cancer

A Arnaout - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Ergocalciferol

Delivery and anti-tumor activity of nanoliposomal irinotecan (Nal-IRI, MM-398) in metastatic xenograft models of triple negative breast cancer

H Lee - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Triple-negative breast cancer

Irinotecan

Evaluation of the impact of oncotype DX test results on systemic therapy in breast cancer patients at the BC cancer agency (BCCA)

V Cheng - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Beta-adrenergic receptor blockers (BB) and increased progression free survival (PFS) in patients with advanced triple negative breast cancer (TNBC): A retrospective analysis of the ROSE/TRIO012 study

G Spera - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Triple-negative breast cancer

Ramucirumab

A prospective evaluation of clinical outcomes in women with pregnancy-associated breast cancer (PABC)

KJ Jerzak - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

CSMD1 SNPs selectively affect anastrozole response in postmenopausal breast cancer patients

J Cairns - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Anastrozole

CS1-2 Clinical utility of multi-gene testing in metastatic breast cancer

P Bedard - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Methadone hydrochloride

Impact of TP53 functional mutation type on clinical outcomes of advanced breast cancer patients

N Stjepanovic - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

TP53

OncotypeDX for breast cancer: A multigene assay that makes a difference?

S Martel - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Prediction of relapse in patients with locally advanced breast cancer after neoadjuvant treatment

O Aseyev - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Trastuzumab

Analytical and clinical validation of a fully automated tissue-based quantitative assay (MetaSite ) to detect the likelihood of distant metastasis in hormone receptor (HR)-positive, HER2-negative early stage breast cancer (ESBC)

MJ Donovan - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Obesity, dyslipidemia, and diabetes as risk factors for trastuzumab-related cardiotoxicity in breast cancer patients

O Aseyev - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Congestive heart failure

Trastuzumab

Refining the prognostic value of Ki67 biomarker by ataxia telangiectasia mutated (ATM) status in a retrospective study of early stage hormone receptor positive breast cancer

X Feng - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Non-genetic risk factors improve accuracy of breast cancer risk assessment for women at high familial risk: Comparison of risk estimation models using the prospective family study cohort (ProF-SC)

MB Terry - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Clinical outcome of patients with advanced triple negative breast cancer with germline and somatic variants in homologous recombination gene

N Stjepanovic - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Triple-negative breast cancer

TP53

Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multi-center trial

HD Bear - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Planning and implementation of two regional one-stop breast health centres within a large geographic health authority: Outcomes and quality improvements in health service delivery

LA Martin - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Filters

28841 Abstracts